P3 Health Partners (PIII) Cash & Equivalents (2019 - 2025)

P3 Health Partners has reported Cash & Equivalents for 7 years, with the latest figure at $25.0 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents fell 35.57% year-over-year to $25.0 million; the trailing twelve-month figure through Dec 2025 stood at $25.0 million (down 35.57% YoY), and the FY2025 full-year result was $25.0 million, down 35.57% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $25.0 million, down from $37.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $110.3 million in Q1 2022, with the low at $4.3 million in Q3 2021.
• Historically, Cash & Equivalents has averaged $38.7 million across 5 years, with a median of $37.0 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Equivalents surged 692.27% — and 2023, when it tumbled 93.48%.
• P3 Health Partners' Cash & Equivalents stood at $5.3 million in 2021, then surged by 230.13% to $17.5 million in 2022, then surged by 107.54% to $36.3 million in 2023, then gained by 6.83% to $38.8 million in 2024, then slumped by 35.57% to $25.0 million in 2025.
• The last three Cash & Equivalents figures came in at $25.0 million (Q4 2025), $37.7 million (Q3 2025), and $38.6 million (Q2 2025), per Business Quant data.